[go: up one dir, main page]

AR037556A1 - Composicion farmaceutica que comprende un abridor del canal de c1c-2 - Google Patents

Composicion farmaceutica que comprende un abridor del canal de c1c-2

Info

Publication number
AR037556A1
AR037556A1 ARP020104435A AR037556A1 AR 037556 A1 AR037556 A1 AR 037556A1 AR P020104435 A ARP020104435 A AR P020104435A AR 037556 A1 AR037556 A1 AR 037556A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
channel opener
composition including
channel
opener
Prior art date
Application number
Other languages
English (en)
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR037556A1 publication Critical patent/AR037556A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Uso de un abridor del canal de C1C-2 para preparar una composición farmacéutica para el tratamiento profiláctico o terapéutico de una condición o enfermedad que responde a la abertura del canal de CIC-2. La composición también es útil para tratar un tejido u órgano a ser transplantado en un procedimiento de transplante.
ARP020104435 2001-11-19 2002-11-19 Composicion farmaceutica que comprende un abridor del canal de c1c-2 AR037556A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33154201P 2001-11-19 2001-11-19

Publications (1)

Publication Number Publication Date
AR037556A1 true AR037556A1 (es) 2004-11-17

Family

ID=23294388

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104435 AR037556A1 (es) 2001-11-19 2002-11-19 Composicion farmaceutica que comprende un abridor del canal de c1c-2

Country Status (12)

Country Link
US (2) US7732487B2 (es)
EP (2) EP1455794B1 (es)
JP (1) JP4377692B2 (es)
AR (1) AR037556A1 (es)
AT (1) ATE498402T1 (es)
AU (1) AU2002348670A1 (es)
CA (1) CA2466906C (es)
DE (1) DE60239220D1 (es)
DK (1) DK1455794T3 (es)
ES (1) ES2359804T3 (es)
TW (1) TWI263505B (es)
WO (1) WO2003043639A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
NZ539582A (en) * 2002-10-23 2007-07-27 Sucampo Ag Prostaglandin compounds for the treatment of obesity
EP1575596B1 (en) * 2002-12-27 2016-06-22 Sucampo AG Derivatives of prostaglandins for treating irritable bowel syndrome and/or functional dyspepsia
US8337891B2 (en) 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI387454B (zh) 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US8962688B2 (en) * 2005-04-12 2015-02-24 Sucampo Ag Method for the treatment of gastrointestinal disorders
ES2389566T3 (es) * 2005-05-17 2012-10-29 Santen Pharmaceutical Co., Ltd. Agente preventivo o terapéutico para tratar un transtorno de la córnea y la conjuntiva
EP2114411A2 (en) * 2007-02-27 2009-11-11 Sucampo AG Composition and method for protecting mitochondria
CN101679328B (zh) * 2007-05-25 2011-12-28 参天制药株式会社 老年黄斑变性的预防或治疗剂
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
JP6710040B2 (ja) * 2015-11-06 2020-06-17 江崎グリコ株式会社 唾液分泌促進剤及び口腔用組成物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5380709A (en) 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
CA1323364C (en) 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
ES2051862T3 (es) * 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para producir un medicamento que tiene un efecto catartico.
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2027814C (en) 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
US5254588A (en) 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
CA2030344C (en) 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
US5256696A (en) 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2030346C (en) 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
DE69130586T2 (de) 1990-05-01 1999-06-17 R-Tech Ueno, Ltd., Osaka Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
US5100647A (en) 1990-10-02 1992-03-31 The Trustees Of The University Of Pennsylvania Method and formulations for the therapy of cystic fibrosis, Bartter's syndrome and secretory diarrheas, and for diuretic treatment
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US6015828A (en) 1996-05-31 2000-01-18 Cuppoletti; John Chemical modification of chloride channels as a treatment for cystic fibrosis and other diseases
ES2310013T3 (es) 1997-11-28 2008-12-16 Sucampo Ag Uso de compuestos de 15-ceto-prostaglandina e como antagonistas de endotelina.
TWI225398B (en) 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
WO2001045691A2 (en) * 1999-12-22 2001-06-28 Inspire Pharmaceuticals, Inc. Method of treating gastrointestinal tract disease with purinergic receptor agonists
AU4472701A (en) 2000-04-06 2001-10-23 Sucampo Ag Bile secretion promoting composition
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
EP1420794B1 (en) 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers

Also Published As

Publication number Publication date
TW200304829A (en) 2003-10-16
EP1455794A2 (en) 2004-09-15
DK1455794T3 (da) 2011-03-14
JP2005515186A (ja) 2005-05-26
TWI263505B (en) 2006-10-11
ES2359804T3 (es) 2011-05-27
WO2003043639A2 (en) 2003-05-30
EP1455794B1 (en) 2011-02-16
CA2466906C (en) 2011-10-18
CA2466906A1 (en) 2003-05-30
US20100204332A1 (en) 2010-08-12
AU2002348670A1 (en) 2003-06-10
EP2364708A3 (en) 2011-12-28
DE60239220D1 (de) 2011-03-31
EP2364708A2 (en) 2011-09-14
JP4377692B2 (ja) 2009-12-02
WO2003043639A3 (en) 2004-02-19
ATE498402T1 (de) 2011-03-15
US20030166632A1 (en) 2003-09-04
US7732487B2 (en) 2010-06-08

Similar Documents

Publication Publication Date Title
AR037556A1 (es) Composicion farmaceutica que comprende un abridor del canal de c1c-2
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
CY1113286T1 (el) Συνθεση με στροντιο και βιταμινη d για την προφυλαξη ή/καιθεραπευτικη αντιμετωπιση των παθησεων των χονδρων ή/και των οστων
TR200201440T2 (tr) Biomedikal kullanım için radyum-223 hazırlanması
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
DE60115842D1 (de) Ventilanordnung
MX9702415A (es) Extractos de cocoa antineoplastica y metodos para elaborar y usar los mismos.
DK1100488T3 (da) Anvendelse af creatinforbindelser til behandling af knogle- eller bruskceller og -væv
ITFI20020145A1 (it) Dispositivo per il trattamento chirurgico del prolasso femminile.
BR0014996A (pt) Método para prevenir ou melhorar a dor de um ferimento fechado cirurgicamente em um indivìduo, e, emplastro
ATE477822T1 (de) Medizinische implantate, prothesen, prothesenteile, medizinische instrumente, geräte und hilfsmittel aus einem halogenid-modifizierten magnesiumwerkstoff
PT1163904E (pt) Composicao para a prevencao de doencas do musculo liso, compreendendo ascorbato, arginina e magnesio
CY1109402T1 (el) Συνθεσεις για κολπικη χρηση
BR0010531A (pt) Composições e usos de et743 para tratamento de câncer
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
MD20020075A (en) Antimicrobial preparation with retarded release of the biologically active component, utilization thereof and process for implant obtaining
HUP0000873A2 (hu) A levobupivakain arcsebészeti alkalmazása
AR037524A1 (es) Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
TR200200278T2 (tr) Kalsilitik bileşimler
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
BRPI0514092A (pt) composição incluindo substáncias naturais com propriedades restauradoras, repelentes e biocida para o tratamento e cura de feridas externas
ATE501719T1 (de) Methoden und zusammensetzungen zur beruhigung von mund- und nasenschleimhäuten
Holder et al. Wound Therapy: With Special Reference to Application of Carbamide-Sulfonamide Mixtures to Contaminated and Infected Wounds
UA42335A (uk) Спосіб лікування гнійних ран

Legal Events

Date Code Title Description
FC Refusal